Surprised By Ascentage Pharma's 58% Slide? What Investors Overlooked
When Ascentage Pharma Group International arrived at ASCO 2026 with fresh data on olverembatinib and a growing list of late stage trials, it looked like the sort of momentum many biotech investors wait for. Investors who held Ascentage Pharma Group International over the past year are down 58.4%, including dividends. If you had been weighing those bullish reports and bearish warnings back on 13 November 2025, what exactly were you betting would happen next?
This theme extends beyond Ascentage Pharma Group International. See which of 123 healthcare AI stocks may still merit a closer look.
The Two Stories Investors Had To Choose Between On Ascentage Pharma Group International
The shares cost HK$67.25 at the start of the period, and anyone looking at Ascentage Pharma Group International had to decide which story felt more convincing.
On the upbeat side, one bullish framework saw a Fair Value of HK$92.81, essentially the price implied if assumptions played out, built on the Takeda collaboration and Olverembatinib trials supporting revenue growth of 74.7% and a future P/E of 59.4x.
The cautious view sketched out a Fair Value of HK$51.97, based on revenue shrinking 3.7% a year and concern that one off Takeda payments and NRDL price pressure could weigh on the business.
What The Results Changed For Ascentage Pharma Group International
ASCO 2026 gave bulls in Ascentage Pharma Group International fresh clinical backing, with olverembatinib and lisaftoclax producing high response rates and manageable safety in difficult leukemias, plus Breakthrough Therapy status for lisaftoclax in China. The financials told a tougher story. Revenue rose from CNY 233.699m to CNY 302.214m, while the loss deepened and net margin fell further to 270.2%. Overall, the evidence pointed in both positive and negative directions.
The key question was whether clinical wins would translate into the earnings profile that the more optimistic case anticipated. For other drug developers, an important check is whether improving trial news comes together with a shrinking loss and a net margin moving toward break even rather than further away.
What You Would Be Paying For In Ascentage Pharma Group International Today
At a current share price of HK$28.1, Ascentage Pharma Group International trades well below where it started one year ago. The analyst consensus Narrative on Simply Wall St sets a Fair Value above that level, built around a bigger role for global hematology oncology rather than domestic China sales.
The Narrative focuses on late stage programs for lisaftoclax and olverembatinib, as well as the Takeda option. A buyer today would therefore need to believe those trials convert into approvals that support a broader revenue base.
"The transition from a China focused developer into a global hematology oncology company with nine ongoing registrational trials, including four cleared by U.S. and European regulators, positions Ascentage Pharma Group International to convert late stage clinical assets into broader geographic revenue and eventually support operating leverage."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
Another Way To Play Blood Cancer
Ascentage shows how much effort goes into new leukemia treatments. You could also look at who is trying to refresh older cancer pillars.
One large drug maker is pouring money into next wave oncology drugs. It is working on new antibody drug conjugates, targeted therapies and personalized vaccines.
The aim is similar to Ascentage, but the starting point is different. Instead of building from scratch, this group is trying to replace its own blockbuster before patents expire.
If that switch works, the business could lean on several cancer treatments instead of one ageing star. That kind of shift can change how investors view future earnings resilience.
That argument has a Narrative and a number behind it. → See the company one Narrative values 26% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com